Now That FDA Approved TG Therapeutics Multiple Sclerosis Treatment, Analyst Are Boosting Price Targets

  • Wednesday, the FDA approved TG Therapeutics Inc's TGTX Briumvi (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS).
  • Briumvi is the first and only anti-CD20 monoclonal antibody approved for RMS that can be administered in a one-hour infusion following the starting dose
  • TG expects to launch Briumvi in the U.S. in 1Q23 commercially. 
  • HC Wainwright reiterates a Buy rating for the stock with a price target of $24, up from $19.
  • The analyst writes that a faster infusion time could enable Briumvi to gain share quickly, and there could be a large opportunity in this indication for a small disruptive sales force. 
  • In the U.S., it is estimated that the top 550 accounts account for >70% of patient volume. A potential European approval could occur in late 2023. 
  • Management has previously noted that about 20% of the global MS sales market for CD20 inhibitors could come from Europe, with the German market being the most important. 
  • Management has not yet decided whether it will partner with Briumvi in Europe or go alone. 
  • HC Wainwright estimates sales of $46.1 million in 2023 for Briumvi in MS, growing to $558.8 million in 2028. 
  • Price Action: TGTX shares are up 18.30% at $10.01 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!